KOLs note that CagriSema could cannibalise semaglutide's market share in obesity due to its improved efficacy.
First results of a dose-escalation study evaluating Clostridium butyricum MIYAIRI 588 (CBM588) with nivolumab/ipilimumab (nivo/ipi) in metastatic renal cell carcinoma (mRCC). This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results